MedTrace Logo

SARS-CoV-2 IgG and IgM Serologic Assays

NCT04562246 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 214

Last updated 2024-02-28

No results posted yet for this study

Summary

The primary objective is to assess and validate the ability of the Beckman Coulter Access COVID-19 IgG and IgM assays to detect immunity in COVID-19 patients in the Henry Ford Hospital Health System.

Conditions

  • Covid19

Interventions

DIAGNOSTIC_TEST

Serologic assays for antibodies to SARS-CoV-2

Beckman Coulter and Roche automated immunoassays

Sponsors & Collaborators

  • Henry Ford Health System

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-14
Primary Completion
2021-03-22
Completion
2024-02-26
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04562246 on ClinicalTrials.gov